Solventum Co. (NYSE:SOLV) Shares Sold by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. lessened its holdings in Solventum Co. (NYSE:SOLV) by 24.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 474 shares of the company’s stock after selling 157 shares during the period. Pinnacle Bancorp Inc.’s holdings in Solventum were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Worldquant Millennium Advisors LLC lifted its holdings in shares of Solventum by 373.6% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after buying an additional 37,600 shares during the period. Harbor Capital Advisors Inc. raised its position in Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after acquiring an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Solventum by 37.4% in the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock valued at $8,217,000 after acquiring an additional 32,051 shares during the period. State Street Corp boosted its position in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Solventum during the 3rd quarter worth approximately $50,948,000.

Solventum Price Performance

NYSE:SOLV opened at $73.60 on Friday. The stock has a 50 day moving average of $69.09 and a two-hundred day moving average of $65.34. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Ratings Changes

Several equities analysts recently issued reports on SOLV shares. Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. Piper Sandler increased their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Mizuho started coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.